TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of High Dose Bowel Preparation Solutions for Patients With Difficult To Clean Colons For Colonoscopy

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients at least 18 years old planning to undergo an elective colonoscopy will be eligible for inclusion in our study if they had a previous colonoscopy with an inadequate preparation.~Exclusion Criteria:~* Patients who are pregnant.~* Patients with ileus, gastrointestinal obstruction, gastric retention, bowel perforation, toxic colitis or toxic megacolon would not be considered elective colonoscopies and are excluded.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Step 1 (Type: None): Patients who had inadequate preparations for colonoscopy with a standard dose of bowel cleansing agent.
- Step 2 (Type: None): Patients who had inadequate preparations for colonoscopy with a step 1 dose of bowel cleansing agent.
- Step 3 (Type: None): Patients who had inadequate preparations for colonoscopy with a step 2 dose of bowel cleansing agent.
- Step 4 (Type: None): Patients who had inadequate preparations for colonoscopy with a step 3 dose of bowel cleansing agent.
- Step 5 (Type: None): Patients who had inadequate preparations for colonoscopy with a step 4 dose of bowel cleansing agent.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Celecoxib Versus Naproxen for Prevention of Recurrent Ulcer Bleeding in Arthritis Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. age \>18,~2. a history of endoscopically proven gastroduodenal ulcer bleeding,~3. H. pylori negative~4. a history of cardiothrombotic disease requiring ASA, and~5. anticipated regular use of NSAIDs for the duration of trial~Exclusion Criteria:~1. concomitant use of anticoagulants;~2. a history of gastric or duodenal surgery other than a patch repair;~3. the presence of erosive esophagitis,~4. gastric outlet obstruction,~5. renal failure (defined by a serum creatinine level of more than 200 umol/L),~6. pregnancy,~7. terminal illness, or~8. cancer

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- NSAID #1 (Type: ACTIVE_COMPARATOR): Celecoxib and Naproxen Placebo
- NSAID #2 (Type: ACTIVE_COMPARATOR): Naproxen and Celecoxib Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Comparative Effectiveness of Sentinel Lymph Node Biopsy for Ductal Carcinoma In Situ

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: RETROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Female DCIS patients older than 67 years and younger than 94 years who were enrolled in a fee-for-service Medicare program and resided in the SEER areas.~* Aim 1: DCIS patients who received breast conserving surgery (BCS) as their first surgery~* Aim 1: DCIS patients who were diagnosed DCIS between January 1998 and December 2011~* Aim 2: DCIS patients who were diagnosed DCIS between January 2001 and December 2013~Exclusion Criteria:~* Aim 1: DCIS patients who received mastectomy as their first surgery~* Aim 2: DCIS patients who received BCS at the beginning yet received mastectomy in the end

- Gender: FEMALE
- Minimum Age: 67 Years
- Maximum Age: 94 Years
- Healthy Volunteers: f

Study Arms:
- Aim 1 Cohort (Type: None): The Aim 1 Cohort is constructed to perform analysis to address study objective Aim 1. This cohort includes patients diagnosed at ages 67-94 years with DCIS between January 1998 and December 2011, and received BCS as their first surgery. Patients in this cohort include those who received sentinel lymph node biopsy (SLNB) and who didn't receive SLNB.~The Aim 1 Cohort and the Aim 2 Cohort can overlap.
- Aim 2 Cohort (Type: None): The Aim 2 Cohort is constructed to perform analysis to address study objective Aim 2. This cohort includes patients diagnosed at ages 67-94 years with DCIS between January 2001 and December 2013, and received BCS as their first surgery. Patients in this cohort include those who received sentinel lymph node biopsy (SLNB) and who didn't receive SLNB.~The Aim 1 Cohort and the Aim 2 Cohort can overlap.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of IDN-6556 in Subjects With NAFLD and Raised Transaminases

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female subjects of minimum adult legal age (according to local laws for signing the informed consent document), able to provide written informed consent, and understand and comply with the requirements of the study~* Diagnosis of non-alcoholic fatty liver disease (NAFLD) as evidenced by imaging or other diagnostic assessments~* Alanine aminotransferase (ALT) levels ≥1.5 x ULN on at least two occasions, seven or more days apart, during the Screening period~* alpha-fetoprotein (AFP) ≤ 100 ng/mL~* Hemoglobin ≥10 g/dL, a platelet count ≥ 100 x 10\^9/L, and a white blood cell count ≥ 3.0 x 10\^9/L~* If on metformin, sulfonylureas, statins, or fibrates, subjects must be on a stable dose of these drugs for at least three months prior to Screening and during the study~Exclusion Criteria:~* Known infection with HIV, HCV, or HBV~* Decompensated or severe liver disease as evidenced by one or more of the following:~  1. Confirmed cirrhosis or suspicion of cirrhosis~ 2. Esophageal varices~ 3. Ascites~ 4. Suspicion of portal hypertension~ 5. Hospitalization for liver disease within 60 days of screening~ 6. Bilirubin \>2 x ULN, or ALT or AST \> 10 x ULN~* Inflammatory bowel disease~* Diagnosed or suspected systemic lupus erythematosus (SLE) and/or rheumatoid arthritis (RA)~* Hepatocellular carcinoma (HCC) at entry into the study~* History of or active non-liver malignancies other than curatively treated skin cancer (basal cell or squamous cell carcinomas)~* Significant systemic or major illness other than liver disease, including coronary artery disease, cerebrovascular disease, pulmonary disease, renal insufficiency, and/or serious psychiatric disease, that, in the opinion of the Investigator would preclude the subject from participating in and completing the study~* History or presence of alcohol abuse, defined as consumption of more than 210 mL of alcohol per week (the equivalent of 14 4-ounce glasses of wine or 14 12-ounce cans/bottles of beer or wine coolers), or other substance abuse within the prior two years

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- IDN-6556 (Type: EXPERIMENTAL): IDN-6556 capsules, 25 mg BID
- Placebo (Type: PLACEBO_COMPARATOR): Placebo BID

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: ToGA Study - A Study of Herceptin (Trastuzumab) in Combination With Chemotherapy Compared With Chemotherapy Alone in Patients With HER2-Positive Advanced Gastric Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adult patients \>=18 years of age~* Inoperable locally advanced, recurrent, and/or metastatic cancer of the stomach or gastro-esophageal junction~* Adenocarcinoma~* HER2-positive tumors~Exclusion Criteria:~* Previous chemotherapy for advanced/metastatic disease~* Lack of physical integrity of the upper gastrointestinal tract, or malabsorption syndrome~* History of cardiac disease~* Dyspnoea at rest, due to complications of advanced malignancy or other disease, or patients who require supportive oxygen therapy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Trastuzumab, Fluoropyrimidine, Cisplatin (Type: EXPERIMENTAL): Participants received an initial loading dose of 8 milligrams per kilogram (mg/kg) trastuzumab i.v. on Day 1 of cycle, followed by 6 mg/kg i.v. every 3 weeks until disease progression; 800 mg/m2 fluorouracil i.v. on Days 1 through 5 of cycle every 3 weeks for 6 cycles; 80 mg/m2 cisplatin i.v. on Day 1 of cycle every 3 weeks for 6 cycles; and 1000 mg/m2 capecitabine p.o. twice daily on Days 1 through 15 of cycle every 3 weeks for 6 cycles.
- Fluoropyrimidine, Cisplatin (Type: ACTIVE_COMPARATOR): Participants received 800 milligrams per square meter (mg/m2) fluorouracil intravenous (i.v.) on Days 1 through 5 of cycle every 3 weeks for 6 cycles; 80 mg/m2 cisplatin i.v. on Day 1 of cycle every 3 weeks for 6 cycles; and 1000 mg/m2 capecitabine orally (p.o.) twice daily on Days 1 through 15 of cycle every 3 weeks for 6 cycles.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Phase 2 Study of Ambrisentan for Liver Function Test Rescue in Pulmonary Arterial Hypertension

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Summary of Inclusion Criteria:~* Males and Females between 12 and 75 years of age~* Current diagnosis of IPAH, FPAH, or PAH associated with collagen vascular disease, congenital systemic-to-pulmonary shunts, anorexigen use, HIV infection~* Must have previously discontinued bosentan or sitaxsentan therapy due to serum aminotransferase (ALT and/or AST) concentrations \> 3 x ULN~* Must have normal (\< 1 x ULN) serum ALT and AST concentrations at screening~* Six-minute Walk distance of at least 150 meters at screening~* If receiving sildenafil or a clinically approved prostanoid for PAH, must have been on stable therapy for at least 4 weeks prior to screening~* Subjects with a diagnosis of HIV must have stable disease status during the screening period

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Sorafenib vs.TransArterial Chemoembolization Plus RadioTherapy in Hepatocellular Carcinoma With Macrovascular Invasion

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age \>19 years~* Child-Pugh class A liver function~* Performance status: Eastern Cooperative Oncology Group (ECOG) score 0 or 1~* Hepatocellular carcinoma (HCC) confirmed by dynamic CT or MRI, or by biopsy~* HCC invasion of first or second branch portal vein or hepatic vein or inferior vena cava~* Reserved unilateral portal blood flow at least in partial~* HCC size larger than 1 cm and less than 50% of total liver volume~* No confirmed extrahepatic metastasis~* Adequate hematopoietic function Hemoglobin ≥ 8.5 g/dL Absolute neutrophil count ≥ 750/mm3 Platelet count ≥ 30,000/mm3~* Creatinine \< 1.5mg/dL~* No plan for pregnancy or breast feeding. Active contraception.~* Willing to give informed consent~Exclusion Criteria:~* Prior history to or exposure of transarterial chemoembolization, external beam radiation to liver, or sorafenib~* Complete obstruction of hepatic outflow~* Confirmed extrahepatic metastasis of HCC~* HCC occupying more than 50% of liver volume~* Uncontrolled ascites of hepatic encephalopathy~* Prior liver transplantation~* Positive for human immunodeficiency virus (HIV)~* Active gastric or duodenal ulcer~* Other uncontrolled comorbidities or malignancy~* Inability to give informed consent

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- TACE+External beam RT (Type: EXPERIMENTAL): Transarterial chemoembolization plus external beam radiation therapy
- Sorafenib (Type: ACTIVE_COMPARATOR): Sorafenib 800 mg/day orally

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Clinical Randomisation of an Antifibrinolytic in Significant Haemorrhage

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~All trauma patients with ongoing significant haemorrhage (systolic blood pressure less than 90 mmHg and/or heart rate more than 110 beats per minute), or who are considered to be at risk of significant haemorrhage, and are within 8 hours of the injury, are eligible for trial entry if they appear to be at least 16 years old. Although entry is allowed up to 8 hours from injury, the earlier that patients can be treated the better.~Exclusion Criteria:~The fundamental eligibility criterion is the responsible doctor's 'uncertainty' as to whether or not to use an antifibrinolytic agent in a particular adult with traumatic haemorrhage. Patients for whom the responsible doctor considers there is a clear indication for antifibrinolytic therapy should not be randomised. Likewise, patients for whom there is considered to be a clear contraindication to antifibrinolytic therapy (such as, perhaps, those who have clinical evidence of a thrombotic disseminated intravascular coagulation) should not be randomised. Where the responsible doctor is substantially uncertain as to whether or not to use an antifibrinolytic, all these patients are eligible for randomisation and should be considered for the trial. There are no other pre-specified exclusion criteria

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Active
- 2 (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: 68-Ga PSMA 11 PET/MRI and 68-Ga RM2 PET/MRI for Evaluation of Prostate Cancer Response to HIFU Therapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Known prostate cancer~* Planned HIFU or HDR local therapy~* Able to provide written consent~* Karnofsky performance status of 50 (or Eastern Cooperative Oncology Group (ECOG) /World Health Organization (WHO) equivalent)~Exclusion Criteria:~* Patients not capable of getting PET study due to weight, claustrophobia, or inability to lay still for the duration of the exam~* Metallic implants (contraindicated for MRI)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 68-Ga RM2+68-Ga PSMA11 (Type: EXPERIMENTAL): 68-Ga RM2 first followed by 68-Ga PSMA11 within 2 weeks. Participant will be injected IV with 140 ± 20% mBq of 68-Ga RM2 OR 3 to 7 mCi of 68-Ga PSMA11
- 68-Ga PSMA11+68-Ga RM2 (Type: EXPERIMENTAL): 68-Ga PSMA11 first followed by 68-Ga RM2 within 2 weeks. Participant will be injected IV with 140 ± 20% mBq of 68-Ga RM2 OR 3 to 7 mCi of 68-Ga PSMA11

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Retrospective Study to Assess the Impact of the Use of Interferon in Patients With Chronic Hepatitis C (DECISION)

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Adult patients, \>/=18 years and \<70 years of age~* Diagnosis of hepatitis C~* Assessment of viral load prior to treatment (mandatory for genotype 1 only)~* Liver biopsy~* Co-morbidities data~* Use of interferon (pegylated or conventional) and ribavirin to treat hepatitis C infection genotype 2 and 3 and pegylated interferon plus ribavirin to treat hepatitis C infection genotype 1~* Above mentioned treatment started between 01-Sep-2007 and 31-Aug-2008~Exclusion Criteria:~* Co-infection with human immunodeficiency virus~* Co-infection with hepatitis B virus~* Presence of hepatocarcinoma~* Patients submitted to hemodialysis~* Organ transplant patients

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Conventional Interferon Plus Ribavirin (Type: None): Eligible participants who will receive conventional interferon plus ribavirin for Chronic Hepatitis C (CHC) according to the standard of care and aligned with the local prescription instructions will be observed during treatment period (48 weeks) and follow up period (24 weeks).
- Peginterferon Alfa-2a Plus Ribavirin (Type: None): Eligible participants who will receive peginterferon alfa-2a plus ribavirin for CHC according to the standard of care and aligned with the local prescription instructions will be observed during treatment period (48 weeks) and follow up period (24 weeks).
- Peginterferon Alfa-2b Plus Ribavirin (Type: None): Eligible participants who will receive peginterferon alfa-2b plus ribavirin for CHC according to the standard of care and aligned with the local prescription instructions will be observed during treatment period (48 weeks) and follow up period (24 weeks).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Ethnic Differences in Response to Topical Capsaicin: A Psychophysical Study on Healthy Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adult men and women who are between 18 and 50 years of age.~* Subjects must be in general good health with no skin disease, disease state or physical condition which would impair evaluation of pain perception or which would increase their health risk by study participation as determined by the investigators.~* Women of childbearing potential will be required to have a negative pregnancy test in order to enroll in the study.~Exclusion Criteria:~* Adults over age 50.~* Children less than 18 years of age.~* Unable to complete the required measures.~* Diagnosis of diseases that would affect the measurement of pain perception.~* Currently enrolled in any investigational study in which the subject is receiving any type of drug, biologic, or non-drug therapy and subjects undergoing treatment with another investigational drug or approved therapy for investigational use within 30 days prior to study participation.~* Use of oral analgesic or other medications known to interfere with pain perception in the week prior to the study.~* Use of emollient on the forearms on the day of the study visit.~* Use of medicated topical preparations on the forearms for the week prior to the study.~* Known history of neuropathy causing diseases such as uremia.~* Known history of uncontrolled thyroid disease.~* Known history of diabetes mellitus.~* Allergy to capsaicin.~* Pregnant women.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: t

Study Arms:
- Capsaicin (Type: ACTIVE_COMPARATOR): Capsaicin 0.1% cream application to the volar side of forearm.
- Placebo moisturizing cream (Type: PLACEBO_COMPARATOR): Placebo moisturizing cream with no active ingredient (Cetaphil; Galderma Laboratories LP, Fort Worth, TX, U.S.A.) to the opposite forearm.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Stress Management Intervention for Caregivers of Patients Undergoing Bone Marrow Transplant (BMT)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* DISEASE CHARACTERISTICS (Meets all of the following criteria):~  * Patient undergoing allogeneic bone marrow transplantation (BMt)~ * Primary caregiver of a BMT patient~ * Has provided care for the patient for at least 50 days of the required 100 days of caregiving following transplant (e.g., 50% of the total time)~* PATIENT CHARACTERISTICS:~  * Able to read and speak English~ * Has telephone access~ * No serious medical condition likely to influence immune and neuroendocrine parameters (caregiver)~ * Alcohol consumption limited to \< 2 drinks/day (caregiver)~ * No history of a psychiatric illness unrelated to the experience as a caregiver within the past 18 months (caregiver)~ * No history of a psychiatric illness unrelated to the BMT within the past 18 months (patient)~Exclusion Criteria:~- PRIOR CONCURRENT THERAPY:~• No concurrent steroid medications (caregiver)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Caregiver Control (Type: NO_INTERVENTION): Orientation class; laboratory biomarker analysis; questionnaire administration; survey administration; treatment as usual psychosocial care.
- Caregiver Intervention (Type: EXPERIMENTAL): Orientation class; laboratory biomarker analysis; questionnaire administration; survey administration; Psychoeducation Paced Respiration and Relaxation (PEPRR), which included one-on-one psychoeducation, stress management intervention, with paced respiration.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete